SCHEMBL25817986

SCHEMBL25817986

CC1(c2cc(NC(=O)Nc3ncc(-c4nn(C5CC5)c5ncnc(N)c45)cn3)on2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NEK7 Q8TDX7 9/20 0.48
KDR P35968 6/20 0.46
SRC P12931 3/20 0.43
PIK3CD O00329 2/20 0.43
ABL1 P00519 2/20 0.43
EGFR P00533 2/20 0.43
HCK P08631 2/20 0.43
PIK3CA P42336 2/20 0.43
PIK3CB P42338 2/20 0.43
MTOR P42345 2/20 0.43
PIK3CG P48736 2/20 0.43
EPHB4 P54760 2/20 0.43
PRKDC P78527 2/20 0.43
PI4KB Q9UBF8 2/20 0.43
RET P07949 6/20 0.43
LCK P06239 2/20 0.43
TEK Q02763 1/20 0.43
FGFR1 P11362 2/20 0.43
FGFR2 P21802 1/20 0.43
FGFR4 P22455 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25793476 0.91 NEK7 (0.48) NEK7KDRSRCPIK3CDABL1
SCHEMBL25793484 0.89 NEK7 (0.60) NEK7KDRSRCPIK3CDABL1
SCHEMBL24096920 0.88 NEK7 (0.63) NEK7KDRSRCPIK3CDABL1
SCHEMBL25817936 0.88 NEK7 (0.50) NEK7KDRSRCPIK3CDABL1
SCHEMBL25817922 0.88 NEK7 (0.47) NEK7KDRSRCEGFRRET
SCHEMBL25793475 0.87 NEK7 (0.60) NEK7KDRSRCPIK3CDABL1
SCHEMBL30486149 0.86 NEK7 (0.59) NEK7KDRSRCLCKTEK
SCHEMBL24096596 0.86 NEK7 (0.59) NEK7KDRSRCLCKTEK
SCHEMBL25817932 0.86 NEK7 (0.50) NEK7KDRSRCPIK3CDABL1
SCHEMBL25793555 0.85 NEK7 (0.65) NEK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203045-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. 2023-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203045-A1 INHIBITORS OF NEK7 KINASE NEK7, NEK1, NEK5 NEK7 1/4885KDR 4072/4885SRC 651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.